Technical Principles and Performance Characteristics of Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method)

Basic detection principle of magnetic particle chemiluminescence method

The Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method) is based on a double-antibody sandwich immunoassay format. The kit contains magnetic particles pre-coated with specific capture antibodies, which can bind to influenza A virus nucleoprotein or matrix protein antigens in the sample. Subsequently, enzyme-labeled detection antibodies are added to form a "magnetic particle-antigen-enzyme-labeled antibody" complex. After separation and washing by magnetic field, a chemiluminescent substrate is added, and the substrate generates a light signal under enzyme catalysis. The light intensity is positively correlated with the antigen concentration in the sample. This technology combines the efficient capture capability of magnetic particles with the sensitive detection of chemiluminescence, enabling quantitative or qualitative analysis of influenza A virus antigens.

Performance comparison with traditional detection methods

Compared with the colloidal gold immunochromatography method, the Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method) generally has higher analytical sensitivity. The minimum detection limit of the colloidal gold method is generally in the range of 10^4–10^5 TCID50/mL, while the chemiluminescence method can reach 10^2–10^3 TCID50/mL. In addition, the magnetic particle chemiluminescence method uses fully automated instrument operation, reducing manual interpretation errors, and results are presented in numerical form, facilitating unified quality control and traceability. Compared with real-time fluorescent PCR, although the chemiluminescence method cannot achieve the amplification sensitivity of nucleic acid testing, its detection time is shorter (usually 30–60 minutes), and the requirements for operators and equipment are lower, making it suitable for rapid screening scenarios such as outpatient and emergency departments and fever clinics.

Key performance indicators and influencing factors

The clinical performance evaluation of the Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method) mainly focuses on sensitivity, specificity, positive predictive value, and negative predictive value. In practical application, the collection quality of sample types (such as nasopharyngeal swabs, oropharyngeal swabs, and nasal washes), viral load, and stage of disease course (higher detection rate within 3 days of onset) can all affect the test results. This kit can generally distinguish influenza A virus from influenza B virus, but cannot perform subtyping (such as H1N1, H3N2, and other subtypes). Some products have good cross-reactivity with epidemic strains such as A/H1N1 pdm09 and A/H3N2, while showing no cross-reactivity with common cold viruses (such as respiratory syncytial virus and adenovirus), ensuring specificity.

Quality control and usage precautions

When using the Influenza A Virus Antigen Detection Kit (Magnetic Particle Chemiluminescence Method), it is necessary to strictly follow the manufacturer's instructions, including sample storage temperature (2–8°C for no more than 24 hours; long-term storage at -20°C is possible but avoid repeated freeze-thaw cycles), reagent equilibration time, instrument calibration and maintenance, etc. It is recommended to set up negative and positive controls during testing to monitor inter-batch differences in reagents and operational standardization. It is worth noting that this kit is an in vitro diagnostic reagent, and the test results are for clinical reference only. They should not be used alone as the sole basis for diagnosis or exclusion, and should be comprehensively judged in combination with epidemiological history, clinical manifestations, and other laboratory tests.